Evidence map›Paper›PMID 37141321›Full record

ArticlePloS one2023

Norwegian version of the Edinburgh cognitive and behavioural ALS screen: Construct validity, internal consistency, inter-rater, and test-retest reliability.

Tina Taule, Irmelin Smith Eide, Line Fjær, Mari-Anne Myrberget, Marit Sofie Oseland, Marit Arnevik Renså, Tone Revheim, Ole-Bjørn Tysnes, Jörg Aßmus, Tiina Rekand

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tina TauleDepartment of Occupational Therapy, Orthopedic Clinic, Haukeland University Hospital, Bergen, Norway.ORCID 0000-0002-9094-347X
Irmelin Smith EideDepartment of Rehabilitation Services, Haraldsplass Deaconess Hospital, Bergen, Norway.
Line FjærDepartment of Physio and Occupational Therapy, Namsos hospital, Nord-Trøndelag Hospital Trust, Namsos, Norway.
Mari-Anne MyrbergetDepartment of Clinical Services, St. Olav's University Hospital, Trondheim, Norway.
Marit Sofie OselandDepartment of Social Work, Occupational Therapy and Physiotherapy, Hospital of Southern Norway, Kristiansand, Norway.ORCID 0000-0002-6809-9313
Marit Arnevik RensåDepartment of Neurology, Neurologic Clinic, Haukeland University Hospital, Bergen, Norway.
Tone RevheimDepartment of Occupational Therapy, Orthopedic Clinic, Haukeland University Hospital, Bergen, Norway.
Ole-Bjørn TysnesDepartment of Neurology, Neurologic Clinic, Haukeland University Hospital, Bergen, Norway.
Jörg AßmusCentre for Clinical Research, Haukeland University Hospital, Bergen, Norway.
Tiina RekandDepartment of Neurology, Neurologic Clinic, Haukeland University Hospital, Bergen, Norway.ORCID 0000-0002-2506-9501

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResearch collaboration highlight a need for validated tests in other languages than English. Translation and culture adjustments may threaten essential features of the original instrument.

objectiveTo assess the internal consistency, inter-rater and test-retest reliability, and construct validity of the Norwegian version of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis (ALS) Screen (ECAS-N).

methodsPerformance of 71 subjects with ALS, 85 healthy controls (HC) and 6 controls with Alzheimer's disease (AD) were assessed with the ECAS-N. Test-retest interval was four months. Internal consistency was evaluated using Cronbach's alpha; reliability was assessed using intraclass correlation coefficient (ICC), Cohen's kappa, and Bland Altman plot. Five hypothesis, including the Montreal Cognitive Assessment (MoCA) screen, was evaluated for construct validity.

resultsECAS-N total score produced a Cronbach's alpha of 0.65, had excellent inter-rater reliability (ICC = 0.99) and acceptable test-retest reliability (ICC = 0.73). Construct validity analysis suggested valid use of the ECAS-N to distinguish people with ALS-specific cognitive impairment from HC (p = 0.001) and those with AD (p = 0.002). The MoCA and ECAS-N were moderately correlated (r = 0.53).

conclusionThe ECAS-N has potential to be used by different testers in clinical practice and research to screen patients with ALS who speak Norwegian and for documenting cognitive impairment over time.

Indexed as

Alzheimer DiseaseAmyotrophic Lateral SclerosisCognition DisordersCognitionHumansLanguageNeuropsychological TestsReproducibility of Results

Identifiers

PMID37141321
PMCPMC10159149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.